MEMBER'S LOGINX
| Invalid Username / Password | ||||||||
| Invalid Captcha | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
Investment in securities market are subject to market risks. Read all the related documents carefully before investing
Grab Our Small Cap Recommendation
Service at a 60% Discount
- Home
- Stock Quote
- BALAXI PHARMA
BALAXI PHARMA Share Price (TARCL)
Here is the latest stock price and chart of BALAXI PHARMA. For more details, see the BALAXI PHARMA company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes |
|---|
| Not listed |
| Live NSE Quotes | Nov 28, 2024 (Close) | ||
|---|---|---|---|
| Price (Rs)79.51 | Open (Rs) 82.50 | High (Rs) 82.70 | Low (Rs) 77.56 |
| % Change-1.36 | Volume 37,047 | Value (Rs) 2,966,752 | 52-Week H/L 151.45 / 74.00 |
| Change | |||||
|---|---|---|---|---|---|
| 1 Day -1.36% | 1 Month -10.90% | 3 Months -25.86% | 1 Year -81.80% | 5 Years (CAGR)* 0.53% | |
* Compound Annual Growth Rate
| BSE Sensex | CNX Nifty |
BALAXI PHARMA Share Price Today:
BALAXI PHARMA last traded price was down 1.4% to Rs 79.5 on the NSE. The total volume of shares traded was 0.0 m.
Overall, the broader S&P BSE HEALTHCARE Index was down by 0.5%. And the benchmark NIFTY 50 was at 23,914.2 (down 1.5%).
Over the last 30 days, the BALAXI PHARMA share price is down 10.9%.
As of September 2024, company promoters held 65.99% stake in BALAXI PHARMA, with no shares having been pledged. To know more, check out the latest shareholding pattern of BALAXI PHARMA.
FAQs on BALAXI PHARMA
What is the BALAXI PHARMA share price today?
On the NSE, BALAXI PHARMA last traded price was down 1.4% at Rs 79.5.
What is the Dividend Yield of BALAXI PHARMA?
For the financial year 2024, BALAXI PHARMA declared dividend amounting to Rs 0.0 per share. At the current price of Rs 79.5, this results in a dividend yield of 0.0%.
Which are the top pharmaceuticals companies in India by marketcap?
Based on marketcap, these are the top pharmaceuticals companies in India:
You can see the full list of pharmaceuticals stocks ranked by marketcap here.
Also, here's one of our more popular screens related to marketcap: India's Biggest Companies by Marketcap.
Which are the biggest pharmaceuticals companies in India by sales?
Based on sales, these are the top pharmaceuticals companies in India:
- #1 SUN PHARMA
- #2 AUROBINDO PHARMA
- #3 DR. REDDYS LAB
- #4 CIPLA
- #5 LUPIN
You can see the full list of pharmaceuticals stocks.
Curious to know which Indian companies are growing their sales at a faster rate than their peers? Check out India's Fastest Growing Companies by Sales.
Which are the biggest pharmaceuticals companies in India by net profit?
Based on net profit, these are the top pharmaceuticals companies in India:
You can see the full list of pharmaceuticals stocks.
In case you are wondering which company logs in the biggest net profit margin in India, check this out: High Profit Margin Companies in India.
Today's Market
![Sensex Today Tanks 1,190 Points | Nifty Ends Below 23,900 | 3 Reasons Why Indian Share Market is Falling]()
Sensex Today Tanks 1,190 Points | Nifty Ends Below 23,900 | 3 Reasons Why Indian Share Market is Falling(Closing)
After starting the day on a flattish note with a positive bias, the benchmarks showcased heightened volatility and ended the day weak.
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Multibagger Penny Stocks
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Best Small-cap Stocks to Buy
- Best Bluechip Stocks to Buy
- Guide to Penny Stocks
- How to Invest in the Share Market
- Warren Buffett - The Value Investor
- Pick the Best Multibagger Stocks
TRENDING TOPICS
Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407
Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com
LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.